Suppr超能文献

Fontan手术后重症监护病房中华法林给药的安全性。

Safety of warfarin dosing in the intensive care unit following the Fontan procedure.

作者信息

Thomas Christopher A, Taylor Kathryn, Schamberger Marcus S, Rotta Alexandre T

出版信息

Congenit Heart Dis. 2014 Jul-Aug;9(4):361-5. doi: 10.1111/chd.12151.

Abstract

OBJECTIVE

To determine the incidence of supratherapeutic international normalized ratio (INR) values in patients initiated on warfarin in the pediatric intensive care unit after the Fontan procedure.

DESIGN

Retrospective chart review.

SETTING

Pediatric intensive care unit in a freestanding pediatric teaching hospital.

PATIENTS

Thirty-two consecutive children with single ventricle physiology with an initial Fontan conversion. All were initiated on warfarin in the postoperative period while in the intensive care unit.

OUTCOME MEASURES

Supratherapeutic INR values, interventions in warfarin dosing to address or prevent supratherapeutic INR values, major and minor bleeding episodes, and venous thromboembolic events.

RESULTS

Supratherapeutic INR values after warfarin initiation occurred in 12.5% (n = 4) of patients with an additional 6.3% (n = 2) requiring dose adjustments due to a rapidly increasing INR. Patients with a supratherapeutic INR were started on warfarin earlier compared with other patients (median postoperative day 2 vs. 5, P = .037, respectively). There were no reported thrombi or thromboembolic events and the only clinically significant bleeding event occurred while the INR value was subtherapeutic.

CONCLUSIONS

Patients undergoing the Fontan procedure may be more sensitive to warfarin dosing when initiated closer to the surgical procedure date. Despite this observation, warfarin appears to be a safe medication for use within the early postoperative period after the Fontan procedure when response to therapy is monitored closely. Clinicians should use caution when initiating warfarin before postoperative day 3 in patients undergoing an initial Fontan operation.

摘要

目的

确定在小儿重症监护病房接受Fontan手术的患者中,华法林起始治疗后国际标准化比值(INR)超治疗范围值的发生率。

设计

回顾性病历审查。

地点

一家独立的儿科教学医院的小儿重症监护病房。

患者

32例连续的单心室生理患儿,首次进行Fontan转换手术。所有患儿在重症监护病房术后均开始使用华法林治疗。

观察指标

INR超治疗范围值、为处理或预防INR超治疗范围值而进行的华法林剂量调整、严重和轻微出血事件以及静脉血栓栓塞事件。

结果

华法林起始治疗后,12.5%(n = 4)的患者出现INR超治疗范围值,另有6.3%(n = 2)的患者因INR迅速升高需要调整剂量。与其他患者相比,INR超治疗范围值的患者更早开始使用华法林(术后中位天数分别为2天和5天,P = 0.037)。未报告血栓或血栓栓塞事件,唯一具有临床意义的出血事件发生在INR值低于治疗范围时。

结论

在Fontan手术日期附近开始使用华法林时,接受Fontan手术的患者可能对华法林剂量更敏感。尽管有此观察结果,但在密切监测治疗反应的情况下,华法林似乎是Fontan手术后早期使用的安全药物。对于首次接受Fontan手术的患者,临床医生在术后第3天之前开始使用华法林时应谨慎。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验